Tisdag 16 December | 07:29:31 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Zelluna: killer cells tackling the solid cancer bottleneck
2025-12-15 14:33:00

Norwegian biotech company Zelluna is rapidly advancing its "off-the-shelf" TCR-NK cell therapies towards clinical development. Following a transformative merger earlier this year, the company has secured positive regulatory feedback from the UK’s MHRA and initiated GMP manufacturing with Catalent. With a cash runway extending into 2027, Zelluna is now fully focused on launching its first-in-human trial with lead candidate ZI-MA4-1. BioStock contacted CEO Namir Hassan to discuss the path ahead.

Read the full interview at biostock.se:

Zelluna's killer cells eliminate bottlenecks in solid cancer
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden